Sierra Oncology, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2003, the company has made substantial strides in developing innovative therapies for patients with cancer, particularly focusing on rare and underserved malignancies. Sierra Oncology is best known for its lead product, momelotinib, a unique treatment designed to address myelofibrosis and other related conditions. This targeted therapy stands out for its ability to alleviate symptoms while also addressing the underlying disease mechanisms. With a commitment to advancing cancer care, Sierra Oncology has established a strong market position, recognised for its dedication to research and development. The company continues to achieve notable milestones, contributing to the evolving landscape of oncology therapeutics.
How does Sierra Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sierra Oncology, Inc.'s score of 100 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sierra Oncology, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with GSK plc, from which it inherits various climate commitments and initiatives. Sierra Oncology's climate commitments are aligned with those of GSK plc, which has established significant reduction targets and initiatives. These include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all aimed at reducing carbon emissions and promoting sustainability. The specific targets and achievements of these initiatives are cascaded from GSK plc, reflecting a commitment to addressing climate change at a corporate level. While Sierra Oncology does not have its own emissions data, it is positioned within a framework that prioritises climate action and sustainability, guided by the overarching goals set by GSK plc. This relationship underscores the importance of corporate responsibility in mitigating climate impacts within the pharmaceutical industry.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 430,000 | 000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sierra Oncology, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.